A case of sudden-onset hearing loss in a patient treated with peginterferon alpha-2b and ribavirin for chronic hepatitis Copen access
- Authors
- Shin, M.K.; Kim, T.H.; Ju, K.; Ha, C.Y.; Min, H.J.; Jung, W.T.; Lee, O.J.
- Issue Date
- 2009
- Keywords
- 만성 C형간염; 페그인터페론; 돌발성 난청; 부작용; Chronic hepatitis C; Peginterferon alfa-2b; Hearing loss; Sudden; Adverse effects
- Citation
- The Korean journal of hepatology, v.15, no.3, pp 370 - 374
- Pages
- 5
- Indexed
- SCOPUS
- Journal Title
- The Korean journal of hepatology
- Volume
- 15
- Number
- 3
- Start Page
- 370
- End Page
- 374
- URI
- https://scholarworks.gnu.ac.kr/handle/sw.gnu/27095
- DOI
- 10.3350/kjhep.2009.15.3.370
- ISSN
- 1738-222X
2093-8047
- Abstract
- Combination therapy of pegylated interferon alpha and ribavirin has been associated with various adverse effects, but sudden-onset hearing loss is uncommon. We report a 60-year-old male patient who developed sudden-onset hearing loss during combination therapy with pegylated interferon alpha and ribavirin for chronic hepatitis C. This patient had been diagnosed with chronic hepatitis C (genotype Ib) and early-stage liver cirrhosis 3 years previously, and had been treated with conventional interferon-alpha and ribavirin for 12 months. However, 6 months from the end of the treatment course the patient relapsed and received combination retreatment with pegylated interferon alpha-2b and ribavirin. He developed sudden-onset right-side hearing loss and tinnitus 42 weeks after the start of this retreatment. Pure-tone audiometry revealed a right-side hearing loss of 60 approximately 90 dB. The patient consequently immediately discontinued the pegylated interferon therapy and was given prednisone 60 mg/day for 10 days, after which the hearing loss had almost completely recovered.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medicine > Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.